Pharmaceutical approaches to eradication of persistent HIV infection.
about
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infectionImmunovirological parameters and cytokines in HIV infectionA stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patientsCross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapyTherapy for persistent HIV.Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavirAdvancements in Developing Strategies for Sterilizing and Functional HIV Cures.Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.BET bromodomain inhibition as a novel strategy for reactivation of HIV-1Re-emergence of the apicomplexan Theileria equi in the United States: elimination of persistent infection and transmission riskThe molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway.Post-treatment control of HIV infection.The transposon-driven evolutionary origin and basis of histone deacetylase functions and limitations in disease prevention.Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationMacrophage polarization and HIV-1 infection.Eliminating the HIV reservoir.Progress and challenges in the use of latent HIV-1 reactivating agentsSimultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry.The viral protein Tat can inhibit the establishment of HIV-1 latency.Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.The latest evidence for possible HIV-1 curative strategies.
P2860
Q21142645-B457A929-79CA-4085-86D6-1FB1EA89CEFBQ26829264-78B726C7-0F24-41CD-AEC2-A105927AABD8Q28477926-AEEED48C-2A87-4F30-A4D0-C13EAED37CE3Q28740329-796AB08D-5B1A-44DA-8E83-6A2FC7852D29Q30386370-9947ECC5-1A8D-41BE-89DB-1850DEFB178FQ33611816-5EFC5AD0-86C6-4946-A767-D1EA3E1A3A5BQ33654409-7D26E780-E7E8-4E95-BB93-5CBA2494CBEDQ33776536-6118EFDC-4E05-44BD-A0E6-0D69CC1EA42FQ33838633-BAF19E33-8138-4593-8AB4-B8519706A7BFQ34032827-FA58D8E1-AC83-4D71-A099-797810041586Q34412745-C0A20237-4E4F-4F6A-8C83-348D9CD2A565Q34544409-6D9C4FB4-4B63-4A1C-80D7-B78613788E7FQ35016964-970E1DA2-19BB-4959-8F9B-3B0937899806Q35113716-113ED2F5-6FFB-4577-8DD9-F8E36F31CD38Q35567047-0CFEF065-EA46-4E25-B38C-7888DD6DFAF8Q36001865-BC0541ED-AE6A-4F1B-AB7E-A0176FB281DBQ36330062-DBE03FED-C502-49F1-854E-57622AB6B903Q37665065-2E82D44D-A482-4487-82BD-61F84962812CQ37993454-A8AB4210-C283-4F12-948A-108D618FA25AQ38509230-665E7F11-8687-4DDF-970D-06999178E1ECQ38583674-3BB3F074-38C3-4D78-AC39-1BC38B8FE841Q39413458-3485B779-B6AC-43E0-A92C-FD363D4BCD46Q47564917-BC1F2876-6954-445D-BF88-9BA4D7C1363CQ52430553-B3FA518F-9187-4D30-833F-9736D5B77702
P2860
Pharmaceutical approaches to eradication of persistent HIV infection.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Pharmaceutical approaches to eradication of persistent HIV infection.
@ast
Pharmaceutical approaches to eradication of persistent HIV infection.
@en
Pharmaceutical approaches to eradication of persistent HIV infection.
@nl
type
label
Pharmaceutical approaches to eradication of persistent HIV infection.
@ast
Pharmaceutical approaches to eradication of persistent HIV infection.
@en
Pharmaceutical approaches to eradication of persistent HIV infection.
@nl
prefLabel
Pharmaceutical approaches to eradication of persistent HIV infection.
@ast
Pharmaceutical approaches to eradication of persistent HIV infection.
@en
Pharmaceutical approaches to eradication of persistent HIV infection.
@nl
P2860
P1476
Pharmaceutical approaches to eradication of persistent HIV infection.
@en
P2093
Mary-Catherine Bowman
Nancie M Archin
P2860
P356
10.1017/S1462399409000970
P577
2009-02-11T00:00:00Z